Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited)

v3.21.2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (unaudited) - USD ($)
$ in Thousands
Series B Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
AOCI Attributable to Parent [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 9 $ 226,524 $ (46) $ (217,070) $ 9,417
Balance, at beginning (in shares) at Dec. 31, 2019 0 8,531,504        
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) $ 13 7,461 7,474
Issuance of common stock in exchange for exercise of warrants in February and March 2020 ($0.57 per share) (in shares)   13,111,999        
Deemed dividend in connection with repricing of November 2019 warrants 451 451
Warrant deemed dividend (451) (451)
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711) 4,602 4,602
Issuance of Series B Convertible preferred stock and common stock warrants in February 2020 ($1,000.00 per share, net of transactional expenses of $711) (in shares) 5,313          
Beneficial conversion feature in connection with issuance of Series B Convertible preferred stock 1,260 1,260
Preferred stock deemed dividend (1,260) (1,260)
Issuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292) $ 4 1,891 1,895
Issuance of common stock and common stock warrants in February 2020 ($0.57 per share, net of transactional expenses of $292) (in shares)   3,837,000        
Issuance of common stock upon conversion of Series B Convertible preferred stock $ 9 (9)
Issuance of common stock upon conversion of Series B Convertible preferred stock (in shares) (5,313) 9,321,053        
Issuance of common stock in March 2020 ($1.10 per share, net of transactional expenses of $1,221) $ 14 14,770 14,784
Issuance of common stock in March 2020 ($1.10 per share, net of transactional expenses of $1,221) (in shares)   14,550,000        
Employee stock purchase plan 2 2
Employee stock purchase plan (in shares)   1,578        
Stock-based compensation 360 360
Foreign currency transaction gain (14) (14)
Net loss (7,273) (7,273)
Balance, at end (in shares) at Mar. 31, 2020 0 49,353,134        
Ending balance, value at Mar. 31, 2020 $ 49 255,601 (60) (224,343) 31,247
Beginning balance, value at Dec. 31, 2019 $ 9 226,524 (46) (217,070) 9,417
Balance, at beginning (in shares) at Dec. 31, 2019 0 8,531,504        
Preferred stock deemed dividend           (1,260)
Net loss           (21,452)
Balance, at end (in shares) at Jun. 30, 2020 0 104,803,906        
Ending balance, value at Jun. 30, 2020 $ 105 292,058 (69) (238,522) 53,572
Beginning balance, value at Mar. 31, 2020 $ 49 255,601 (60) (224,343) 31,247
Balance, at beginning (in shares) at Mar. 31, 2020 0 49,353,134        
Preferred stock deemed dividend          
Issuance of common stock under 2019 Purchase Agreement   $ 1 277     278
Issuance of common stock under 2019 Purchase Agreement (in shares)   464,471        
Issuance of common stock in May and June 2020 under At-the-market offering, net of transaction expenses of $1,131 $ 53 34,089 34,142
Issuance of common stock in May and June 2020 under At-the-market offering, net of transaction expenses of $1,131 (in shares) 0 52,986,301        
Issuance of common stock in the acquisition of Trigemina assets $ 2 1,358 1,360
Issuance of common stock in the acquisition of Trigemina assets (in shares)   2,000,000        
Stock-based compensation 733 733
Foreign currency transaction gain (9) (9)
Net loss (14,179) (14,179)
Balance, at end (in shares) at Jun. 30, 2020 0 104,803,906        
Ending balance, value at Jun. 30, 2020 $ 105 292,058 (69) (238,522) 53,572
Beginning balance, value at Dec. 31, 2020 $ 206 355,037 (62) (267,533) 87,648
Balance, at beginning (in shares) at Dec. 31, 2020 0 206,008,683        
Issuance of common stock in exchange for exercise of warrants in March 2021 ($0.57 per share) 2 2
Issuance of common stock in exchange for exercise of warrants in March 2021 ($0.57 per share) (in shares) 0 3,400        
Issuance of common stock in January 2021 ($0.80 per share), net of transactional expenses of $3,096 $ 50 36,854 36,904
Issuance of common stock in January 2021 ($0.80 per share), net of transactional expenses of $3,096 (in shares)   50,000,000        
Issuance of common stock in February 2021 ($1.20 per share), net of transactional expenses of $5,002 $ 58 64,939 64,997
Issuance of common stock in February 2021 ($1.20 per share), net of transactional expenses of $5,002 (in shares)   58,333,334        
Issuance of common stock in January 2021 under At-the-market offering, net of transactional expenses of $230 $ 10 6,769 6,779
Issuance of common stock in January 2021 under At-the-market offering, net of transactional expenses of $230 (in shares)   9,517,867        
Employee stock purchase plan 28 28
Employee stock purchase plan (in shares)   54,447        
Stock-based compensation 1,212 1,212
Foreign currency transaction gain (1) (1)
Net loss (20,653) (20,653)
Balance, at end (in shares) at Mar. 31, 2021 0 323,917,731        
Ending balance, value at Mar. 31, 2021 $ 324 464,841 (63) (288,186) 176,916
Beginning balance, value at Dec. 31, 2020 $ 206 355,037 (62) (267,533) 87,648
Balance, at beginning (in shares) at Dec. 31, 2020 0 206,008,683        
Preferred stock deemed dividend          
Net loss           (44,206)
Balance, at end (in shares) at Jun. 30, 2021 0 346,358,451        
Ending balance, value at Jun. 30, 2021 $ 346 491,957 (71) (311,739) 180,493
Beginning balance, value at Mar. 31, 2021 $ 324 464,841 (63) (288,186) 176,916
Balance, at beginning (in shares) at Mar. 31, 2021 0 323,917,731        
Preferred stock deemed dividend          
Issuance of common stock in April and June 2021 under At-the-market offering, net of transactional expenses of $612 $ 16 18,686 18,702
Issuance of common stock in April and June 2021 under At-the-market offering, net of transactional expenses of $612 (in shares) 0 15,658,426        
Issuance of commitment shares under 2021 Purchase Agreement
Issuance of commitment shares under 2021 Purchase Agreement (in shares)   1,280,000        
Issuance of common stock under 2021 Purchase Agreement $ 3 3,344 3,347
Issuance of common stock under 2021 Purchase agreement (in shares)   2,750,000        
Issuance of common stock in the acquisition of the OyaGen license $ 3 2,997 3,000
Issuance of common stock in the acquisition of the OyaGen license (in shares)   2,752,294        
Stock-based compensation 2,089 2,089
Foreign currency transaction gain (8) (8)
Net loss (23,553) (23,553)
Balance, at end (in shares) at Jun. 30, 2021 0 346,358,451        
Ending balance, value at Jun. 30, 2021 $ 346 $ 491,957 $ (71) $ (311,739) $ 180,493